BTIG reiterates Buy on Abivax, maintains $150 target
BTIG analyst Julian Harrison has reiterated a Buy rating for Abivax (NASDAQ: ABVX) and maintained a $150 price target. The move reflects continued confidence in the company's growth prospects.
*this image is generated using AI for illustrative purposes only.
BTIG analyst Julian Harrison has reaffirmed a Buy rating for Abivax (NASDAQ: ABVX), maintaining a price target of $150. The reiteration underscores the firm's continued confidence in the stock's potential.
Analyst Rating and Target
The rating update follows a review of Abivax's market position. The $150 price target suggests significant upside from current levels, reflecting the analyst's positive outlook on the company's future performance.
| Metric | Value |
|---|---|
| Rating | Buy |
| Price Target | $150 |
| Analyst | Julian Harrison |
| Firm | BTIG |
Market Context
Abivax is listed on the NASDAQ under the ticker symbol ABVX. The reiteration of the Buy rating indicates that BTIG sees favorable risk-reward dynamics for the stock at this stage.
What upcoming clinical milestones could drive the stock toward the $150 price target?
How might Abivax's competitive landscape evolve in the near term?
What are the key risks that could prevent the stock from reaching BTIG's target?
19
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
